NASDAQ : BLSM
BlossomHill Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 15.21 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 483.45M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Selling, General & Admin | 9.95M | 7.89M | 4.59M |
| Research & Development | 75.29M | 56.14M | 31.81M |
| Operating Expenses | 85.24M | 64.02M | 36.40M |
| Operating Income | -85.24M | -64.02M | -36.40M |
| Interest & Investment Income | 3.66M | 3.48M | 5.71M |
| Currency Exchange Gain (Loss) | -17.00K | -11.00K | |
| Pretax Income | -81.60M | -60.55M | -30.70M |
| Net Income | -81.60M | -60.55M | -30.70M |
| Net Income to Common | -81.60M | -60.55M | -30.70M |
| Shares Outstanding (Basic) | 2.56M | 2.44M | 2.29M |
| Shares Outstanding (Diluted) | 2.56M | 2.44M | 2.29M |
| EPS (Basic) | -31.83 | -24.83 | -13.40 |
| EPS (Diluted) | -31.83 | -24.83 | -13.40 |
| Free Cash Flow | -71.06M | -47.99M | -31.51M |
| Free Cash Flow Per Share | -27.72 | -19.68 | -13.76 |
| EBITDA | -84.74M | -63.58M | -36.05M |
| D&A For EBITDA | 504.00K | 441.00K | 350.00K |
| EBIT | -85.24M | -64.02M | -36.40M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Cash & Equivalents | 95.38M | 136.68M | 100.15M |
| Cash & Short-Term Investments | 95.38M | 136.68M | 100.15M |
| Prepaid Expenses | 2.59M | 2.14M | 4.03M |
| Total Current Assets | 100.97M | 138.83M | 104.17M |
| Property, Plant & Equipment | 20.69M | 21.65M | 1.59M |
| Other Long-Term Assets | 2.48M | 2.50M | 1.02M |
| Total Assets | 124.13M | 162.97M | 106.78M |
| Accounts Payable | 3.93M | 2.31M | 849.00K |
| Accrued Expenses | 12.73M | 13.16M | 5.40M |
| Current Portion of Leases | 1.15M | 5.00K | 525.00K |
| Total Current Liabilities | 18.62M | 15.48M | 6.77M |
| Long-Term Leases | 22.22M | 22.39M | |
| Total Liabilities | 42.09M | 37.87M | 6.77M |
| Common Stock | 1.00K | 1.00K | 1.00K |
| Additional Paid-In Capital | 5.01M | 3.30M | 1.59M |
| Retained Earnings | -179.79M | -135.03M | -74.47M |
| Total Common Equity | -174.78M | -131.73M | -72.88M |
| Shareholders' Equity | 82.04M | 125.09M | 100.00M |
| Total Liabilities & Equity | 124.13M | 162.97M | 106.78M |
| Total Debt | 23.37M | 22.40M | 525.00K |
| Net Cash (Debt) | 72.00M | 114.28M | 99.62M |
| Net Cash Per Share | 28.08 | 46.87 | 43.50 |
| Filing Date Shares Outstanding | 31.78M | 2.55M | 2.29M |
| Total Common Shares Outstanding | 2.77M | 2.55M | 2.29M |
| Working Capital | 82.35M | 123.35M | 97.40M |
| Book Value Per Share | -63.15 | -51.68 | -31.82 |
| Tangible Book Value | -174.78M | -131.73M | -72.88M |
| Tangible Book Value Per Share | -63.15 | -51.68 | -31.82 |
| Machinery | 2.62M | 1.87M | |
| Leasehold Improvements | 268.00K | 103.00K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Net Income | -81.60M | -60.55M | -30.70M |
| Depreciation & Amortization | 504.00K | 441.00K | 350.00K |
| Stock-Based Compensation | 1.50M | 1.09M | 504.00K |
| Other Operating Activities | 1.53M | 1.29M | 697.00K |
| Change in Accounts Payable | 3.26M | 1.47M | -1.14M |
| Change in Other Net Operating Assets | 3.82M | 9.35M | -1.13M |
| Operating Cash Flow | -70.98M | -46.92M | -31.42M |
| Capital Expenditures | -83.00K | -1.07M | -92.00K |
| Investing Cash Flow | -83.00K | -1.07M | -92.00K |
| Issuance of Common Stock | 3.38M | 589.00K | 420.00K |
| Financing Cash Flow | 87.32M | 84.53M | 17.56M |
| Net Cash Flow | 16.26M | 36.53M | -13.95M |
| Free Cash Flow | -71.06M | -47.99M | -31.51M |
| Free Cash Flow Per Share | -27.72 | -19.68 | -13.76 |
| Levered Free Cash Flow | -28.44M | ||
| Unlevered Free Cash Flow | -28.44M | ||
| Change in Working Capital | 7.08M | 10.81M | -2.27M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Market Capitalization | 394.77M | ||
| Enterprise Value | 322.76M | ||
| Debt / Equity Ratio | 0.28 | 0.18 | 0.01 |
| Net Debt / Equity Ratio | -0.88 | -0.91 | -1.00 |
| Net Debt / EBITDA Ratio | 0.85 | 1.80 | 2.76 |
| Net Debt / FCF Ratio | 1.01 | 2.38 | 3.16 |
| Quick Ratio | 5.12 | 8.83 | 14.79 |
| Current Ratio | 5.42 | 8.97 | 15.38 |
| Return on Equity (ROE) | -53.80% | ||
| Return on Assets (ROA) | -29.67% | ||
| Return on Capital Employed (ROCE) | -80.80% | -43.40% | -36.40% |
| Buyback Yield / Dilution | -6.47% |